Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...

CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino ...

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin. With the 2025 European Society of Medical Oncology (ESMO) Congress starting on ...

A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...

When the organization now called the European Society for Medical Oncology (ESMO) opens its 50th anniversary Congress ...

University of Arizona Cancer Center researchers will study the potential effects of the loss of the Y chromosome in the ...

Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.

Researchers in China combined findings from MRI scans with clinical features to create a new predictive model for nonmuscle-invasive bladder cancer recurrence.

U of A Comprehensive Cancer Center Director Dr. Dan Theodorescu plans to study loss of Y chromosome biology and investigate ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Hamas Releases All 20 Surviving Hostages Under Gaza Ceasefire Deal As Trump Arrives In Israel Pastor shot by ICE with pepper ...